InMode Ltd.
inmodemd.comWhat Do They Do?
Sells energy-based medical aesthetic platforms for surgeons, dermatologists and OB/GYNs treating face, body and women’s wellness concerns.
20-F for FY2025, filed Feb 10, 2026
How Do They Make Money?
Physicians and distributors pay for platforms and consumables. Product sales happen when items ship; end users usually pay upon delivery, while distributors make a down payment and pay within several months, and some North American end users use installment financing.
20-F for FY2025, filed Feb 10, 2026Revenues from product sales are recognized when the customer obtains control over the Company’s product, typically upon shipment to the…View ↗
Payment terms and conditions vary by customer. The Company’s standard terms for end users usually require of payment upon delivery and for…View ↗
The Company may enter into installment sales contracts with end users in North America that provide them with long-term (generally up to 60…View ↗
-
20-F for FY2025, filed Feb 10, 2026
FY2025 revenue by product or service ↗
$370.5M
-
20-F for FY2025, filed Feb 10, 2026
$370.5M ↗
| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Capital Equipment Revenues
Sold outright
20-F for FY2025, filed Feb 10, 2026 |
78%
FY2022: 87%
|
Capital Equipment Revenues, FY2025
$289.1M Sources
|
Sold outright |
|
Consumables And Service Revenues
|
22%
FY2022: 13%
|
Consumables And Service Revenues, FY2025
$81.4M Sources
|
Who Are Their Customers?
Physicians, including aesthetic surgeons, dermatologists and OB/GYNs, are its historic customers; InMode sells directly in its direct-sales markets and through distributors in other countries.
20-F for FY2025, filed Feb 10, 2026Our primary strategy to increase market penetration relies on selling directly to our historic customer base of plastic and facial…View ↗
We currently sell and market our products in the United States, Canada, the United Kingdom, Ireland, Spain, Portugal, France, Belgium…View ↗
In international markets, to complement our direct sales force, we sell our products through a network of distributors. Our Canadian sales…View ↗
Do Revenues Turn Into Profits?
Yes. It kept 25 cents of every revenue dollar as net income in FY2025 and turned 23 cents into free cash flow.
20-F for FY2025, filed Feb 10, 2026
$85.4MView ↗
20-F for FY2025, filed Feb 10, 2026
$93.8MView ↗
20-F for FY2025, filed Feb 10, 2026
$84.3MView ↗
How Are They Changing?
Flat. Revenue was $370.5M in FY2025, about the same as the $357.6M of FY2021.
Dry-eye treatment
The older report described an ophthalmology platform with a dry-eye handpiece in development; the latest report lists treatment of dry eyes among its platform applications.
20-F for FY2022, filed Feb 14, 2023 20-F for FY2025, filed Feb 10, 2026Treatment of dry eyesView ↗
Urology applications
The older report described an RF device for erectile dysfunction as in early development; the latest report says ApexRF was brought to market for temporary relief of muscle spasms and improved local blood circulation.
20-F for FY2022, filed Feb 14, 2023 20-F for FY2025, filed Feb 10, 2026For urologists, we are in the early-stages of developing a device using RF energy to treat ED (Erectile Dysfunction). We registered a…View ↗
For urologists, we brought to the market a device using RF energy to for temporary relief of muscle spasms, and temporary improvement of…View ↗
Loading...
